Asia Healthcare Analyst, Pathology Associates Limited

Dion Stéfan Büchner M.D., FCAP

Asia Healthcare Analyst

Pathology Associates Limited

Equity Bottom-Up

While sales of Takeda's long listed products (~ 20% of sales in FY15) continue to decline, expectations remain bleak for its late stage pipeline.We see Trintellix as one of the key building blocks (after Ninlaro and Entyvio) that, despite a modest contribution to top-line sales, is expected to provide much required stability to Takeda’s topline over the next five years.In the absence of label expansion to treat cognitive dysfunction, we project Trintellix to generate ~US$700m at peak for the…

While sales of Takeda's long listed products (~ 20% of sales in FY15) continue to decline, expectations remain bleak for its late stage pipeline.We see Trintellix as one of the key building blocks (after Ninlaro and Entyvio) that, despite a modest contribution to top-line sales, is expected to provide much required stability to Takeda’s topline over the next five years.In the absence of label expansion to treat cognitive dysfunction, we project Trintellix to generate ~US$700m at peak for the…

Trintellix (Vortioxetine) – Selective Serotonin Reuptake Inhibitor (SSRI) And Partial Agonist

<ul>
<li>Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead of scheduled PDUFA), for treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).</li>
<li>In the EU, Ninlaro was granted accelerated assessment by EMA in Jul-15 and received conditional approval on 24th Nov’16, following a re-examination of the committee’s earlier negative opinion on its risk/benefit profile.</li>
<li>By virtue of being first and the only oral…</li>
</ul>


Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead of scheduled PDUFA), for treating patients with Relapsed/Refractory Multiple Myeloma (RRMM).
In the EU, Ninlaro was granted accelerated assessment by EMA in Jul-15 and received conditional approval on 24th Nov’16, following a re-examination of the committee’s earlier negative opinion on its risk/benefit profile.
By virtue of being first and the only oral…


Ninlaro (Ixazomib) - Oral Proteasome Inhibitor

Thematic (Sector/Industry)

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment landscape for non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), myeloadysplastic syndrome (MDS) and acute myeloid leukemia (AML).Data on several novel programs were presented; we review select companies based on our standard abstract assessment methodology. We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria…

American Society of Hematology- (ASH) Annual Conference (2016) Review

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (<a href="http://www.hematology.org/Annual-Meeting/" target="_blank">ASH – 2016</a>) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at the upcoming American Society of Hematology (ASH – 2016) conference in San Diego this weekend.We use our proprietary ranking methodology (PRM) to rank concerned abstracts on seven criteria (mechanism of action, clinical phase, indication, route of administration, study design, safety profile and efficacy profile) and assign weight to each criterion...

American Society of Hematology (ASH) -Annual Conference (2016) Preview

SGX Market Strategist, Equity & Fixed Income, Singapore Exchange Ltd (SGX)

Geoff Howie

SGX Market Strategist, Equity & Fixed Income

Asia’s leading multi-asset exchange

Singapore Exchange Ltd (SGX)

Singapore Exchange is Asia’s leading and trusted market infrastructure, facilitating the exchange of capital and ideas to create value for people, businesses and economies. As a multi-asset exchange operating equity, fixed income and derivatives markets to the highest regulatory standards, SGX is a vertically integrated business that provides listing, trading, clearing, settlement, depository and data services.

With about 40% of listed companies and over 80% of listed bonds originating outside of Singapore as well as established linkages across the region and in Europe, SGX is Asia’s most international and connected exchange. Offering a full suite of derivatives products across Asian equity indices, commodities and currencies, SGX is the world’s most liquid international market for the benchmark equity indices of China, India, Japan and ASEAN.

As Asia’s pioneering central counterparty, SGX is globally recognised for its risk management and clearing capabilities, and was one of the first globally to adopt the Principles for Financial Market Infrastructure.

Headquartered in AAA-rated Singapore, SGX has over 800 employees including offices in Beijing, Chicago, Hong Kong, London, New York, Mumbai, San Francisco, Shanghai and Tokyo.

The first 10 months of 2016 brought its fair share of macroeconomic challenges to the region. During the 10 months, the Straits Times Index (STI) generated a 1% total return, which was not far behind that of the MSCI AC Asia Pacific Index. However, the 1% gain is hardly the full story for the 30 STI stocks in the year thus far.  All five Global Industry Classification Standards (GICS®) Sectors without STI representation also generated gains over the first 10 months. These Sectors are also at junctures of opportunity and challenge, with Sector-wide themes such as technology disruptors, population longevity &amp; growth and asymmetric trends in commodity prices. The five Sectors have also become increasingly important for investors who seek portfolio diversification in times of increased economic uncertainty.

The first 10 months of 2016 brought its fair share of macroeconomic challenges to the region. During the 10 months, the Straits Times Index (STI) generated a 1% total return, which was not far behind that of the MSCI AC Asia Pacific Index. However, the 1% gain is hardly the full story for the 30 STI stocks in the year thus far.  All five Global Industry Classification Standards (GICS®) Sectors without STI representation also generated gains over the first 10 months. These Sectors are also at junctures of opportunity and challenge, with Sector-wide themes such as technology disruptors, population longevity &amp; growth and asymmetric trends in commodity prices. The five Sectors have also become increasingly important for investors who seek portfolio diversification in times of increased economic uncertainty. 

Buoyant Returns Beyond the Benchmark in 2016 YTD

Japan

Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Takeda Pharmaceutical (4502 JP)

Trintellix (Vortioxetine) – Selective Serotonin Reuptake Inhibitor (SSRI) And Partial Agonist

While sales of Takeda's long listed products (~ 20% of sales in FY15) continue to decline, expectations remain bleak for its late stage pipeline.We...

Dion Stéfan Büchner M.D., FCAP

Ninlaro (Ixazomib) - Oral Proteasome Inhibitor

Ninlaro (ixazomib, formerly MLN9708, Takeda) is the first and the only oral proteasome inhibitor, approved by USFDA (Nov’15) (three months ahead...

Dion Stéfan Büchner M.D., FCAP

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

Dion Stéfan Büchner M.D., FCAP

American Society of Hematology (ASH) -Annual Conference (2016) Preview

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...

Dion Stéfan Büchner M.D., FCAP

Buoyant Returns Beyond the Benchmark in 2016 YTD

The first 10 months of 2016 brought its fair share of macroeconomic challenges to the region. During the 10 months, the Straits Times Index (STI)...

Singapore Exchange Ltd (SGX)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)